1. Home
  2. AVXL vs PACK Comparison

AVXL vs PACK Comparison

Compare AVXL & PACK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • PACK
  • Stock Information
  • Founded
  • AVXL 2004
  • PACK 1972
  • Country
  • AVXL United States
  • PACK United States
  • Employees
  • AVXL N/A
  • PACK N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • PACK Containers/Packaging
  • Sector
  • AVXL Health Care
  • PACK Consumer Discretionary
  • Exchange
  • AVXL Nasdaq
  • PACK Nasdaq
  • Market Cap
  • AVXL 794.0M
  • PACK 590.3M
  • IPO Year
  • AVXL N/A
  • PACK N/A
  • Fundamental
  • Price
  • AVXL $9.32
  • PACK $3.62
  • Analyst Decision
  • AVXL Strong Buy
  • PACK Buy
  • Analyst Count
  • AVXL 2
  • PACK 2
  • Target Price
  • AVXL $44.00
  • PACK $5.50
  • AVG Volume (30 Days)
  • AVXL 927.5K
  • PACK 320.7K
  • Earning Date
  • AVXL 08-05-2025
  • PACK 07-31-2025
  • Dividend Yield
  • AVXL N/A
  • PACK N/A
  • EPS Growth
  • AVXL N/A
  • PACK N/A
  • EPS
  • AVXL N/A
  • PACK N/A
  • Revenue
  • AVXL N/A
  • PACK $374,800,000.00
  • Revenue This Year
  • AVXL N/A
  • PACK $9.69
  • Revenue Next Year
  • AVXL N/A
  • PACK $8.27
  • P/E Ratio
  • AVXL N/A
  • PACK N/A
  • Revenue Growth
  • AVXL N/A
  • PACK 10.11
  • 52 Week Low
  • AVXL $4.00
  • PACK $2.91
  • 52 Week High
  • AVXL $14.44
  • PACK $9.04
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 60.62
  • PACK 50.08
  • Support Level
  • AVXL $9.09
  • PACK $3.47
  • Resistance Level
  • AVXL $9.78
  • PACK $3.66
  • Average True Range (ATR)
  • AVXL 0.41
  • PACK 0.14
  • MACD
  • AVXL 0.09
  • PACK 0.02
  • Stochastic Oscillator
  • AVXL 71.58
  • PACK 53.22

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of revenue from Europe/Asia. They generate revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and our network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency.

Share on Social Networks: